Chinese Sle Treatment And Research Group
Clinical trials sponsored by Chinese Sle Treatment And Research Group, explained in plain language.
-
New trial aims to find best treatment for lung complication in rheumatoid arthritis
Disease control Not yet recruitingThis 52-week study will compare three drugs—tocilizumab, telitacicept, and methotrexate—in 204 people with rheumatoid arthritis who also have interstitial lung disease. The main goal is to see which drug best improves lung function. Participants will continue their usual arthriti…
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. R…
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug firsekibart aims to tame lupus flares in Hard-to-Treat patients
Disease control Not yet recruitingThis pilot study tests Firsekibart, a biologic that blocks IL-1, in 15 adults with mild to moderate lupus who still have symptoms despite standard therapy. Participants receive three shots over 8 weeks, then stop the drug to see if symptoms return. The goal is to see if this appr…
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC